百度(09888.HK)LinearDesign完成生物實驗驗證
百度(09888.HK)和mRNA藥物公司斯微生物宣佈,百度mRNA疫苗序列設計算法LinearDesign完成在新冠病毒mRNA疫苗分子設計上的生物學驗證。在穩定性、蛋白質表達水平及免疫原性等關鍵指標上,LinearDesign設計的疫苗大幅優於傳統方法的設計,證明應用於生物製藥領域的商業價值。
實驗研究結果顯示,由LinearDesign設計的mRNA分子,其結構緊密度、溶液中穩定性、蛋白質表達水平及動物免疫原性均超過用傳統方法設計的mRNA分子。尤其是抗原中和抗體滴度指標上,LinearDesign設計的分子最高超過基準分子的20倍。
除了應用於新冠病毒mRNA疫苗的研發,LinearDesign算法還能用於傳染病疫苗、腫瘤疫苗、單抗藥物等各種疫苗和藥物的研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.